Santhera Pharmaceuticals Holding AG SANN

Pratteln, Switzerland, July 13, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone), extending the partnership to include Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan, for the treatment of Duchenne muscular dystrophy (DMD) in patients two years of age and older. Biomedica was originally appointed as a distributor for AGAMREE® in October 2025. Under the expanded agreement, Biomedica wi

Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases Pratteln, Switzerland, July 1, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes topline results from a two-part Phase 1 clinical study of AGAMREE® conducted by its North American licensing partner, Catalyst Pharmaceuticals, Inc. ("Catalyst"). The study suggests that AGAMREE® delivers glucocorticoid and anti-inflammatory activity, while avoiding significant immunosuppressive effe